E.A.S .E .
E.A.S.E
PROJEC T PULS E_ _
NOTE: TH I S J O URN A L I S TH E P RO P E RTY OF TH E E X P E RI M E N TA L A S S O C IATION FO R S CI E N TI FI C E VO LUTI O N(E . A. S. E)
DATE:
21.01.2310
All experiments were conducted within our laboratories with the exclusion of studies conducted in facilities overseas.
All research and experiments were done under the strict supervision and approval of the team leads of PULSE.
E.A.S.E
21. 01. 2310
CLAUSES A N D R E G U L AT I O N S 1. This journal is to remain in the records vault of the E.A.S.E headquarters unless requested to be brought out for referencing purposes. The journal is not to be brought back to personal living quarters or offices. 2. All information, research and recordings in this journal are not to be breached or shared with outside parties, including close acquaintances and family members. Leakage of information will be traced and dealt with by the chief officers of E.A.S.E. 3. All members involved in the contribution of this journal are to understand the risks and precautions involved and are to abide with the agreements stated. 3. All experiments and tests are to be conducted within the facilities of E.A.S.E unless given permission under special circumstances. 4. All experiments and tests are to be recorded and tagged with their subsequent code numbers. Secret experimentations will lead to severe consequences. 5. Routine checks will be conducted frequently to ensure the lab journals are at their place in the vault. Missing journals will be reported immediately and traced. 6. Any personel suspected to attempt a leakage of information or experimentations done in secrecy are to be reported immediately. 7. All members involved in the contribution of this project are not allowed to back out until the completion of the project except under special circumstances.
CONTENT
CONTENT
ABOUT E.A.S.E.
01
PULSE TEAM
02
OVERVIEW
03
TIMELINE
05
PAST RESEARCH AND STUDIES
07
STUDY: HUMAN BLOOD AND PLASTICS
09
EQUIPMENT AND MACHINE CHECK-01
11
T E S T - T 0 1 A N D A N A LY S I S
13
T E S T - T 0 2 A N D A N A LY S I S
18
T E S T - T 0 3 A N D A N A LY S I S
25
EQUIPMENT AND MACHINE CHECK-02
33
SUBJECTS PROFILE
35
SUBJECT MONITOR
37
E.A.S.E
ABOUT E.A.S.E
The Ex pe rime n ta l A s so c i at i o n Fo r S c i e n t i f i c Evolution (E. A. S. E) w as e st ab l i s he d i n 2 07 0 by a g roup of sci en tis ts th a t w i s he d t o m ake a c h an ge i n t h e evolut ion of ma n kin d t hro u g h d ar i n g e x p e r i m ent a t ions . In 2088 , d ue to our v i si o n of ac hi e v i n g m o re a nd t h e di ffere n ce s be twe en o u r go al s, E .A .S .E l e f t t h e U nit ed S ci ence N a tion a n d fo r m e d o u r ve r y o w n g ro u nd s and pr a ctice s . Sin ce t h e n , w e have b e e n co n d uct ing experime n ts on our o w n an d have c am e u p w i t h va rious new i n ve n tion s a n d c u re s t hat has g re at ly b e nef it ed t owards h e a lth ca re an d t he e co n o m y. Movi n g forwa rd, E. A .S .E p l an s t o co n t i n u e b e i ng a revolu tion a ry force i n t he s c i e n t i f i c f i e l d w i t h our b old t ri als a n d re s e a rch , e ve n i f w e are f ace d w i t h ris ks a nd cri t i cis m tow a rd s o u r p r ac t i ce s fo r t h e g re at e r good .
01
TEAM
‘PULSE’ TEAM LEADS
RESEARCHERS
DR J. WARNEY HEAD OF L A B O R ATO R Y A N D E X P E R I M E N TAT I O N S
PROFFESOR DOFF DIVISION OF MEDICAL SCIENCES
DR H. SOO HEAD OF HUMAN STUDIES
MS REINKE DIVISION OF HUMAN STUDIES
SCIENTISTS
O P E R AT O R S
DR DINAH HEAD OF MEDICAL SCIENCES
MS HELENA HEAD OF EQUIPMENT AND MACHINERIES
D R N AT HEAD OF M AT E R I A L R E S E A R C H DR RUGHON HEAD OF MOLECULAR M O D I F I C AT I O N S
M R W. R AY DIVISON OF EQUIPMENT AND MACHINERIES
02
E.A.S.E
21. 01. 2310
OVERVIEW: PROJECT PULSE THE STUDY OF SYNTHETIC HUMAN BLOOD REPLACEMENT
INTRODUCTION
Since the beginning of heathcare, there has long been a need for blood substitutes when it comes to the human body. Look at the problems we have faced with human blood—people who die from excessive bleeding in accidents, issues with blood transfusions, donated blood having a short shelf-life, etc. With our increasing population growth and vast advancement in science and technology, it is even more apparent for us to act now and attempt a revolutionary invention that could change the whole field of medical sciences. With the concerns that were mentioned before, the study of a blood replacement has thus been a crucial research subject for scientists and doctors alike, and there has been attempts in developing substitues for the human blood. This is of course no easy feat and records have shown that this is an effort that had started all the way back in the 1600s.
REFERENCE: Suman Sarkar, Artificial blood (2008) Indian J Crit Care Med; 12(3): 140–144.DOI: 10.4103/0972-5229.43685
03
The types of blood substitutes attempted include the usage of milk, animal blood, crystal salt solutions and several chemical solvents. However, they were all deemed not suitable as they all still had a short shelf-life and loses its blood-like functions over time. The closest finding to a breakthrough came in the 2000s, where researchers found a substitute by merging plastics in blood, thus promising a replacement that will last longer.
OVERVIEW
However, with the technological tools available at that time, the project could not continue and the study was thus abandoned. With the techonological advancements of today, E.A.S.E was inspired to reopen this study again and has recently discovered a new form of plastic compound that holds close resemblance to that of the human blood composition. The potential of this discovery thus led to the project PULSE, aimed at the research and development of this new compound as a blood substitute.
OBJECTIVES
The new synthetic blood developed in PULSE should ideally fulfill the following requirements. The blood should be compatible with the human body and suitable for blood transfusions, no matter the blood type of the human carrier. The new blood should not raise any contamination issues or viruses, which means it would have to be a recognisable substance to the white blood cells. The blood must of course be able to perform the functions of human blood or more, such as transporting oxygen throughout the bloodstreams and releasing carbon dioxide when necessary. The visocity and solubilty of the new blood will also have to be considered as it should flow well through the blood vessels and eliminate the risk of blood clotting. Apart from that, the new blood should have a shelf-life of 6 months and above, an improvement from normal blood which can only be stored for 1. The newly developed blood will go through several tests and trials before it is ready to be tried on human subjects. The ultimate goal of course, would be to experiment the usage of the developed PULSE blood on the human body so as to produce a more concrete outcome and hypothesis. The subjects will then be monitored for over a year to check whether the new blood is functioning well in their bloodstreams as well as to study the effects of the PULSE blood on their bodies. If successful, the new blood will enter the second stage of mass development. .
SIGNED BY
DR J WARNEY
DR H SOO
JW
HS 04
E.A.S.E
TIMELINE E S T I M AT E
21.01.2310
15.03.2310 —31.06.2310
PROJECT PULSE COMMENCES
FURTHER TESTS A N D A N A LY S I S
05
24.01.2310
01.03.2310
EQUIPMENT CHECK AND TESTING 01
TEST 01 OF FIRST PULSE SAMPLE
2 7. 0 1 . 2 3 1 0 —28.02.2310
0 1 . 07. 2 3 1 0
P R E PA R AT I O N AND FURTHER RESEARCH
FINAL VERSION OF PULSE TO BE DEVELOPED
TIMELINE
01.08.2310 EXPERIMENTS ON TEST SUBJECTS
01.01.2311 —31.12.2311 MONITORING OF TEST SUBJECTS
01.01.2312 PHASE 1 END
01.11.2310 T E S T R E S U LT S A N D A N A LY S I S
EXPECTED DEADLINE
01.2312
(PHASE 1)
ACKNOWLEDGED BY E.A.S.E AND THE TEAM OF PULSE
06
E.A.S.E
PAST RESEARCH AND STUDIES
YR 2007
‘SHEFFIELD SCIENTISTS DEVELOP ARTIFICIAL BLOOD’
DEPARTMENT OF CHEMISTRY
10 MAY 2007
UNIVERSITY OF SHEFFIELD, UNITED KINGDOM
Scientists from the University of Sheffield are developing an artificial 'plastic blood', which could act as a substitute for real blood in emergency situations. The 'plastic blood', which will be on display at the Science Museum this month, could have a huge impact on military applications. Because the artificial blood is made from a plastic, it is light to carry and easy to store. Doctors could store the substitute as a thick paste in a blood bag and then dissolve it in water just before giving it to patients – meaning it’s easier to transport than liquid blood.
ARCHIVED
Donated blood has a relatively short shelf-life of 35 days, after which it must be thrown away. It also needs refrigeration, whereas the ‘plastic blood’ will be storable for many more days and is stable at room temperature.
Fig 01. Excerpt 01 of Sheffield Scientist develop ‘Artificial blood’.
07
PAST STUDIES
The artificial blood is made of plastic molecules that hold an iron atom at their core, just like haemoglobin, that can bind oxygen and could transport it around the body. The small plastic molecules join together in a tree-like branching structure, with a size and shape very similar to that of natural haemoglobin molecules. This creates the right environment for the iron to bind oxygen in the lungs and release it in the body.
Fig 02. Excerpt 02 of Sheffield Scientist develop ‘Artificial blood’.
While still in its development, the scientists hope this will make it particularly useful for military applications and being plastic, it’s also affordable. The scientists are now seeking further funding to develop a final prototype that would be suitable for biological testing. Dr Lance Twyman, from the Department of Chemistry at the University of Sheffield and who has been developing the artificial blood for the last five years, said: “We are very excited about the potential for this product and about the fact that this could save lives.
Fig 03. Excerpt 03 of Sheffield Scientist develop ‘Artificial blood’
SOURCE: ‘Sheffield Scientist develop Artificial blood’ (2007),University of Sheffield. Retrieved from: https://www.sheffield.ac.uk/news/nr/808-1.175169
08
E.A.S.E
23. 01. 2310
STUDY: HUMAN BLOOD AND PLASTICS THE FUNCTION OF BLOOD IN HOMOSAPIENS.
ABSTRACT
clot parts of blood to heal wounds or attack harmful bacteria that enters the body.
This is a summarised version of the research and findings the team has done in preparation for this project.
The components of the blood are made up of the red blood cells(erythrocytes), white blood cells(leukocytes), platelets, and the plasma. Further breaking down the components of the blood will lead us to proteins, which includes the plasma-proteins, as well as the the metalloprotein, haemogloblin. This iron substance as we all know, is responsible for the oxygen-carrying function in blood.
Keywords: Blood, plastics, synthetic blood.
The blood is a lifesaving fluid or tissue that is present all around the human body. Many also call it an organ since it performs crucial functions that helps keep the body working. Its numerous functions includes of course, transporting oxygen and removing carbon dioxide from the bodily cells. Besides the circulatory tract, blood also helps with the digestive system by transporting nutrients and waste from the intestines and the kidneys. The components present in blood also have protective properties, where they
09
When it comes to blood transfusion, one should note that the haemoglobin level should be 13.5 g/dl or more and weigh more than 65 kg. The platelet count should be 150,000/mm3 or more, the white cell count and differential count should be within normal limits although the synthetic blood developed with PULSE should only mainly replace the properties and functions of the red blood cells.
STUDY
Plastics on the other hand, which in this case, the thermoplastic, polyethylene, is a light-weight and durable polymer that has been manufactured and popularly used in the 2000s as a form of material for numerous packaging or living quarters neccessities.
E.A.S.E finally reached a breakthrough when we developed a new composite polymer that was found to have a composition similar to the red blood cells of the existing human blood(Figure 01), though it still needs more research to reach a concrete consensus.
The polymer has a number of high-performing properties, such as its toughness, chemical inertness, low coefficient friction as well as low electrical conductivity. Most importantly, it has a particularly versatile and mallaeble molecular crystalline structure, allowing the polymer to morph and adapt into whichever form it is needed for.
This study shows us the potential of this project in producing synthetic blood and this brings us one step closer to our goals. There were also clarifications made about the precautions the team will have to make while prepping for the future development and trials of the new blood substance.
Through the years, polyethylene has since been developed for various other applications outside of just being a material. It wasn’t until recently that we discovered a new lead that could allow it to branch onto medical science. While E.A.S.E was researching on plastics as candidates for the blood substitutes, we saw a potential in the adaptable property of polyethylene. We modified the polymer to fulfill certain qualities. The result will need to have coupling agents that would attach the polymer to blood substances, forming strong covalent bonds instead of Van der Waals.
OH
H
O
O
O
O x
Fig 04. Molecular composition of Human Blood.
SOURCES 01. Debdatta Basu, Rajendra Kulkarni (2014), Overview of blood components and their preparation, Indian J Anaesth.58(5): 529–537. DOI: 10.4103/0019-5049.144647
02. P. Noorunnisa Khanam, Mariam Al Ali AlMaadeed (2015) Processing and characterization of polyethylenebased composites, Advanced Manufacturing: Polymer & Composites Science, 63-79 DOI: 10.1179/2055035915Y.0000000002
10
E.A.S.E
EQUIPMENT AND MACHINES USED
EQUIPMENT CHECKED AND TESTED BY MS HELENA
HC 24. 01. 2310
MAIN PROCEDURES:
MIXING OF BLOOD A N D P O LY E H T H Y L E N E E X A M I N AT I O N A N D D O C U M E N TAT I O N UNDER MICROSCOPE
VCH MICROSCOPE
11
EQUIPMENT CHECK-01
EVANS MIXER
X M - X LV H 1
12
E.A.S.E
B ATC H 0 1 TEST CODE: L125 01. 03. 2310
T E S TÂ-T 0 1 DESCRIPTION:
The first batch of PULSE blood was developed by the Laboratories of E.A.S.E using a fusion of the new polymer composite and components from the plasma of human blood. A sample from the batch was tested and analysed. Key analysis includes molecular structure, solubility and compatability with the human body.
MACHINES AND EQUIPMENT USED:
TRANSFUSIONER VCH MICROSCOPE X M - X LV H 1 EVANS MIXER
Fig 05. Sample from Batch 01 of PULSE, Date: 01. 03. 2310.
13
TEST-T01
Fig 06. Close-up cellular view of Sample L125, Date: 01. 03. 2310.
Fig 07. Substance view of Sample L125, Date: 01. 03. 2310.
14
E.A.S.E
Fig 08. Microscopic composition of PULSE Sample 01—Magnifiedx20, Date: 01. 03. 2310.
15
TEST-T01
Fig 09. Microscopic composition of PULSE Sample 01—Magnifiedx50, Date: 01. 03. 2310.
REMARKS: Sample L125 shows a more ‘plastic-ish’ composition than a bloodlike composition. The outcomes are too blur and unclear to determine the inner structure or solubility of the sample. This could be due to an uneven mixture of the blood and the poly material during fusion. More dosage of haemogloblin mix is to be issued to the next sample. Analysis of the sample will not be continued till clearer results are produced. Better, much efficient equipment will have to be used as well. Request for magnification at x200 for the next batches of tests.
DR H.SOO 03. 03. 2310
16
E.A.S.E
SAMPLE L125
5 0 % M ATC H
HUMAN BODY
*PULSE will only be subjected to tests on human subjects when data match reaches 85% and above.
17
TEST-T02
B ATC H 0 2 TEST CODE: L235 09. 04. 2310
T E S TÂ-T 0 2 DESCRIPTION:
The second batch of PULSE blood developed by the Laboratories of E.A.S.E. The dosage of leukocytes and haemoglobin was increased in this batch of samples. A sample from the batch was tested and analysed. Key analysis includes molecular structure, solubility and compatability with the human body.
MACHINES AND EQUIPMENT CHANGE:
XM3000 USED INSTEAD OF XM-LXVH1 M A G N I F I C AT I O N INCREASED TO X200
Fig 10. Sample from Batch 02 of PULSE, Date: 09. 04. 2310.
18
E.A.S.E
Fig 11. Microscopic composition of PULSE Sample 02—Magnifiedx20, Date: 09. 04. 2310. 19
TEST-T02
Fig 12. Microscopic composition of PULSE Sample 02—Magnifiedx200, Date: 09. 04. 2310. 20
E.A.S.E
D ATA A N AY L S I S
15. 04. 2310
20
15
L235 AVERAGE
COMPOSITION— NEW COMPOUNDS:
10
P O LY A L K Y L E N E 05
HAPTOGLOBIN FLUOROCARBON P O LY E T H Y L E N E
00
00
02
05
Fig 13. Units of RBC duplicated in Sample L235.
RECORDED BY MS REINKE
RC
21
The total amount of RBC was increased in the new blood sample, allowing the haemoglobin to transport oxygen more efficiently. The erythrocytes concentration is nearly as close, though the addition of polyalkylene and polyethylene binds the blood thickness more tightly and would result in the release of lesser oxygen to the body tissue and individual cells.
TEST-TO2
SAMPLE L235 COMPOSITION
O H
H
O HUMAN BLOOD COMPOSITION
O
OH
H
O
O
O
O x
M AT C H I N G COMPOUNDS:
A—OXYGEN B—CHLORIDE C—HYDROGEN D—HAEMOGLOBIN E — P O LY S A C C H A R I D E
The study of the composition of sample L235 in comparision with that of the human blood shows its structural similarities and we filtered out their matching compounds. This is a promising outcome, although just for precautionary measures, the following compounds input should be increased in accordance to the percentages present below.
A 10%
B 23%
C 22%
D 10%
E 22%
22
E.A.S.E
C O M PATA B I L I T Y D I A G R A M
23
R A D I AT I O N D I S TA N C E S
SOLUBILITY: 0.025MOL/L
3.2
AT O M I C RADIUS
PH7
RADIAL SIZING
50%
AT O M I C RADIUS-2
TEST-T02
SAMPLE L235
7 0 % M ATC H
HUMAN BODY
*PULSE will only be subjected to tests on human subjects when data match reaches 85% and above.
24
E.A.S.E
B ATC H 0 3 TEST CODE: L436 15. 05. 2310
T E S TÂ-T 0 3 DESCRIPTION:
The third batch of PULSE blood developed by the Laboratories of E.A.S.E. The dosage of erythrocytes, polysaccharide and chloride was increased in this batch of samples. A sample from the batch was tested and analysed. Key analysis includes polypeptide studies and compatability with the human body.
MACHINES AND EQUIPMENT XM3000 M A G N I F I C AT I O N S T I L L AT X 2 0 A N D X 2 0 0
Fig 14. Sample from Batch 03 of PULSE, Date: 15. 05. 2310.
25
TEST-T03
Fig 15. Microscopic composition of PULSE Sample 03—Magnifiedx20, Date: 15. 05. 2310.
26
E.A.S.E
Fig 16. Microscopic composition of PULSE Sample 03—Magnifiedx200-1, Date: 15. 05. 2310.
27
TEST-T03
Fig 17. Microscopic composition of PULSE Sample 03—Magnifiedx200-2, Date: 15. 05. 2310.
28
E.A.S.E
30. 05. 2310
D ATA - O 3 A N AY L S I S P O LY P E P T I D E CHAIN SEQUENCES:
A — P O LY A L K Y L E N E B—HAPTOGLOBIN C—FLUOROCARBON D — P O LY E T H Y L E N E E — P O LY S A C C H A R I D E
49% A
55% B
65% C
80% D
49% E
L E V E L S O F P O LY P E P T I D E S E Q U E N C E S
Human erythrocyte membranes were boiled and dissolved to determine the molecular weights of the constituent proteins. The process realases the polypeptide chains labelled A, B , C ,D and E which we measured and tried to duplicate into the new PULSE sample. The cells’ recgonitive properties will register the new substances as amino acids substitutes.
Fig 18. New protein structure.
29
DATA-03
PROTEIN AND AMINO ACID SEQUENCES IN SAMPLE L436 PRESENTED IN A DITHER DIAGRAM:
___________________________________MHOO1 3 HOFNA2
Z LOU
A34
3 MCHOA1
TRIY78
00 AA
A35
XX GLOU
LYSA6
8 THR
A6
9 SERA7
VALA9
11 LYS
A9
12 THRA10
LEUA12
14 TRP
A12
LYSA15 4 VALC1
3 SOR
-7 ASP
B1
C3
-37 TRPC4
39 THR
OX
40 ARGC7
42 TYR
B7
38 MHOO1
69 GLYE14
65 ALA
E14
70 ALAE15
72 SERE17
68 ASN
E17
-73 ASPE18
75 LEUE20
71 ALA
APF
PHE
GH5
122 MHOO1
XX1
H9
129 LEU GLYH15
TYR
O H15
135 VAL
142 ALAH21 HO2
127 LYS
134 VALH13
132 VAL
139 ASNH18 H20
118 THR
131 GLNH10 H12
GH3
145 TYRHC3
H10
H13
141 ARG
125 LEU 128 PHE
135 ALAH14
133 SER
H16
136 LEU
143 HISHC1 HC3
GH4
1
H19 139 LYS
A14
39 GLNC6
17
41 THR
64 ASP
XXX
67 THR
E16
70 VAL
-121 GLUGH5 H8
E19 1 87
130 TYRH9
H11
131 SER
133 VALH12 H14
138 ALAH17 141 LEUH20 HC1
14
38 THR
74 GLYE19
116 GLU
132 LYSH11
140 ALAH19 H21
E18
11
A11
16 LYS
71 PHEE16
129 ALAH8
137 VALH16
138 SER
V15
8
A8
36 PROC3 C5
-1
A4
13 ALA
68 LEUE13
69 ALA
120 LYSGH4
130 ALA
H18
E12
90 LPU
H1
O2
40 LYS
41 PHECE1
XXX XXX
10 VAL
16 GLYA14
37 PRO
NB2
56 ILS
13 ALAA11
A30
35 TYRCI
1 OAL
45 THRA2
10 ALAA8
A11
15 GLY
SDA1
7 MCHOA1
A4
12 ALA
B4
A2
A3
9 ASN
15 TRPA13
36 PHE
CH1 NAL
136
134 THR
H17
137 THR
144 LYSHC2
140
IXX X_____________________________
30
E.A.S.E
SAMPLE L436
9 2 % M ATC H
HUMAN BODY
T H I S S A M P L E I S S U I TA B L E F O R T E S T S A N D E X P E R I M E N TAT I O N S ON HUMAN SUBJECTS.
31
TEST-T03
REMARKS:
With the switch of equipment and x200 magnification, we were successful in capturing the desired outcomes in samples L235 and L436. In L235, we could already make out some blood cell-like features present in the PULSE sample and with x200 magnification, we were able to zoom in on the modified red blood cells and see the polyethylene composite binding the substances together. This was a promising result and we ran it for data analysis. After some rectifications, we came up with the new batch L436 in Test-T03 and under magnification found that this sample has the most resemblance to the normal human blood without losing the polyethylene composite properties, bringing us the closest to our desired result. Further tests and analysis shows that the sample has passed all compatability tests and matching sequences, confirming that the new sample has fulfilled all the qualities needed for a synthetic blood, bringing the human body compatability percentage to 92%. I am glad to affirm that this new sample is ready for the project’s next stage— experimentations on actual human bodies.
DR J WARNEY 11. 06. 2310
32
E.A.S.E
KEY PROCEDURE IN TRANSFUSION HUMAN BLOOD PULSE FUSION
EQUIPMENT CHECKED AND TESTED BY MS HELENA
HC 20. 06. 2310
VACUUM TRANSFUSIONER
33
EQUIPMENT CHECK-02
PULSE ENTERS BLOODSTREAM THROUGH OSMOSIS
PULSE
X-RBC
34
E.A.S.E
1 2 . 07. 2 3 1 0
SUBJECTS PROFILE The subjects involved have all agreed to partake in this experiment for the benefit of scientific evolution and the development of mankind.
TEST CODE: P101
SCOUTED AND APPROVED BY DR SOO.
PROCEDURE:
Subjects will go through blood transfusion of PULSE at 50cc. Thereafter they will be injected with daily dosages.
M01
35
N01
SUBJECTS PROFILE
SUBJECT M01:
FEMALE, 27 S T A T U S : H E A LT H Y , ABLE-BODIED H E I G H T: 1 6 0 C M W E I G H T: 5 2 KG BLOOD TYPE: O NO ALLERGIES NO HISTORY OF MEDICAL ILLNESS
ORIGINS: DISTRICT X
DNA STRUCTURE:
36
E.A.S.E
10. 08. 2310
SUBJECT M01 MONITOR: Day 01 since subject was injected with PULSE batch L436.
S TAT U S : H E A LT H Y , N O R M A L
BLOOD LEVELS
MAIN COMPONENTS: IRON PULSE WAT E R GLUCOSE SODIUM
30% Glucose
37
17% Sodium
47% Iron
58.1% PULSE
23% Water
M01 MONITOR
H E A R T R AT E : ECG HH(32)
+0.5 X S L-1 M M
BPM
70
BP
111/60 X 32.1 MAX-
REMARKS: S ub j ec t’s vita ls a re w e l l an d sh e i s f u n c t i o n i n g a s p er norma l. Subje ct wil l co n t i n u e d o sage of P UL S E L436. Keep s ubje ct in th e w hi t e ro o m w h i l e b e i n g m o nit ored .
DR H.SOO 10. 08. 2310
38
E.A.S.E
! A L E RT: SUBJECT M01
12. 08. 2310
S TAT U S : CRITICAL Day 03 since subject was injected with PULSE batch L436.
REPORT Subject‘s heart rate plummeted below 50 at 15.03.
H E A R T R AT E M O N I TO R AT 1 5 . 3 5 ECG HH(32)
+0.5 X S L-1 M M
39
BPM
40
M01-MONITOR
U P D AT E D I N T I M E W I T H THE SUBJECT’S TRACKER
16.00: Subject rushed for treatment and diagnosis.
16.10: Subject transfused with normal human blood.
16.30: Subject’s heart rate drops to 10.
1 7. 0 0 : Resuscitation efforts has been carried out for 30 mins.
PRONOUNCED DEAD T I M E O F D E AT H : 1 7. 2 0
40
PROJECT HALTED_ _ _
E.A.S .E .